3,615 trials (keyword fallback)
Advanced Ovarian Cancer · Primary Peritoneal Cancer · Advanced Breast Cancer
Primary: Percent of Participants Who Achieve a Sustained Progressive Disease (PD) Response, Defined to be at Least 4% Nuclear Area Positive (NAP) γH2AX at the Day 8 Biopsy — 44.4…
Solid Tumors
Primary: To Establish the Safety and Tolerability of Single-agent AZD1775 in Patients With Refractory Solid Tumors — 6; 4; 6; 3 Participants
Solid Tumor · Anaplastic Thyroid Cancer
Primary: Maximum Tolerated Dose (MTD) of Cisplatin (Phase I) — 100 mg/m^2
Neuroblastoma · Sarcoma · Rhabdomyosarcoma-Embryonal
Primary: Number of Participants With a Positive Immune Response as Evidenced by the Delayed Type of Hypersensitivity (DTH) Reaction Assay — 0; 15 Participants — p=0.043
Lymphomas · Solid Tumors · NSCLC
Primary: Phase 2: Response Rate of This Combination in Participants With Colon Cancer, Non-small Cell Lung Cancer (NSCLC), and Granulosa Cell Ovarian Cancer — 0; 0; 0; 1…
Head and Neck Cancer
Primary: Number of Participants With Side Effects After Ad/PNP-F-araAMP Treatment — 12; 8; 8; 5 participants
Malignant Solid Tumor - Malignant Nervous System Neoplasm
Primary: Phase 1: Maximum Tolerated Dose of Cabazitaxel — 30 mg/m^2
Abdominal Trauma
Primary: Sensitivity of Detecting Solid Organ Injury Measured as the Number of True Positives — 18; 20 Participants
Melanoma · Solid Tumors
Primary: Parts 1, 2, 4, and 5: Number of Participants Who Experienced Dose-limiting Toxicities (DLTs) — 1; 1; 1; 2 Participants
Solid Neoplasms With NTRK Fusions
Primary: Duration of Response (DoR) — 24.5 months
Neoplasm
Primary: Part A: Number of Patients With Dose Limiting Toxicities (DLTs) in the MTD Evaluation Period — 1; 0; 2 Participants
Rectal Adenocarcinoma · Stage II Rectal Cancer AJCC v7 · Stage III Rectal Cancer AJCC v7
Primary: Pathologic Complete Response Rate — 17 percentage of participants
Metastatic Melanoma
Primary: Complete Response — 7; 3 Participants
Liver Cancer
Primary: Median Progression-free Survival
Lung Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Safety and Toxicity of Erlotinib Hydrochloride and Docetaxel as Measured by NCI CTC v3.0 on Day 8 of Course 1 and on Day 1 of Every Subsequent Course (Phase I [Completed…